Quantinno Capital Management LP Raises Holdings in Grifols, S.A. $GRFS

Quantinno Capital Management LP increased its holdings in Grifols, S.A. (NASDAQ:GRFS) by 42.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 352,798 shares of the biotechnology company’s stock after purchasing an additional 104,418 shares during the period. Quantinno Capital Management LP owned approximately 0.05% of Grifols worth $2,829,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GRFS. Bank of Montreal Can lifted its stake in shares of Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after acquiring an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after purchasing an additional 2,221,633 shares during the period. Norges Bank bought a new position in shares of Grifols during the fourth quarter valued at approximately $18,139,000. Brandes Investment Partners LP increased its holdings in Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after buying an additional 1,838,727 shares during the period. Finally, Barclays PLC increased its holdings in Grifols by 132.6% during the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock valued at $22,764,000 after buying an additional 1,387,783 shares during the period.

Grifols Price Performance

Shares of Grifols stock opened at $7.94 on Monday. The firm’s 50 day moving average price is $7.50 and its 200-day moving average price is $8.13. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. Grifols, S.A. has a 52-week low of $6.96 and a 52-week high of $10.84. The company has a market cap of $5.40 billion, a P/E ratio of 41.79, a PEG ratio of 0.29 and a beta of 0.66.

Grifols Announces Dividend

The company also recently declared a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were issued a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is currently 121.05%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Weiss Ratings lowered Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, July 31st. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.